← Back to signals
RXST
INSIDER SELLRxSight, Inc.
Research: Finviz ↗·Perplexity ↗
No convergence signal this quarter — shown because tracked funds have filed 13D/G on this stock.
Days to cover (short int.)
4.6d↑+2.8%
as of 2026-09-30
News Summary
NegativeRxSight secured a transformative $200M Alcon partnership and installed new leadership, but this was overshadowed by a 19% product sales decline in Q2 2026, withdrawn full-year guidance, and a cascade of analyst downgrades to 'Sell'/'Reduce' consensus. The stock has lost 48% over 12 months amid persistent commercial headwinds and investor litigation risk.
Red flags
- •Q2 product sales declined 19% year-over-year with LAL unit volumes down 9%
- •Full-year 2026 guidance withdrawn; new guidance deferred to early 2027, signaling management uncertainty
- •Revised 2026 core sales guidance cut to $110–$120M (from prior $120–$135M)
- •Stock down 48% over 12 months; closed at $4.67 vs. 52-week high of $13.22
- •12 analyst firms holding 'Reduce' consensus with average price target $8.17 (vs. then-current price ~$4.67)
- •Multiple downgrades (Wall Street Zen to 'Sell', BofA PT cut to $5.50, Weiss 'sell')
- •Securities litigation investigation announced (Glancy Prongay Wolke & Rotter LLP)
- •New CEO and CMO appointed mid-quarter, indicating prior strategic misalignment
Insider Activity
Fund 13D/13G Filings (1)
Tracked funds' beneficial-ownership filings on this stock — disclosed within days of a position change, fresher than the quarterly 13F. Since Filing compares the stock to SPY from the filing date (shown for filings within the last 90 days).